Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Blood (2010) 116 (9): 1460–1468.

https://doi.org/10.1182/blood-2009-06-222943

Published: 2010

Includes: Supplemental data

Journal Articles

Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Teru Hideshima, Hiroshi Ikeda, Dharminder Chauhan, Yutaka Okawa, Noopur Raje, Klaus Podar, Constantine Mitsiades, Nikhil C. Munshi, Paul G. Richardson, Ruben D. Carrasco, Kenneth C. Anderson

Blood (2009) 114 (5): 1046–1052.

https://doi.org/10.1182/blood-2009-01-199604

Published: 2009

Includes: Supplemental data

Journal Articles

Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications

Teru Hideshima, Dharminder Chauhan, Tanyel Kiziltepe, Hiroshi Ikeda, Yutaka Okawa, Klaus Podar, Noopur Raje, Alexei Protopopov, Nikhil C. Munshi, Paul G. Richardson, Ruben D. Carrasco, Kenneth C. Anderson

Blood (2009) 113 (21): 5228–5236.

https://doi.org/10.1182/blood-2008-06-161505

Published: 2009

Journal Articles

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

Yutaka Okawa, Teru Hideshima, Paul Steed, Sonia Vallet, Steven Hall, Ken Huang, John Rice, Amy Barabasz, Brianna Foley, Hiroshi Ikeda, Noopur Raje, Tanyel Kiziltepe, Hiroshi Yasui, Sotaro Enatsu, Kenneth C. Anderson

Blood (2009) 113 (4): 846–855.

https://doi.org/10.1182/blood-2008-04-151928

Published: 2009

Includes: Supplemental data

Journal Articles

AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β

Loredana Santo, MD, Sonia Vallet, M.D., Teru Hideshima, M.D., Ph.D., Diana Cirstea, MD, Samantha Pozzi, MD, Nileshwari Vaghela, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, Gullu Gorgun, PhD, Giulia Perrone, MD, Elisabetta Calabrese, MD, Matthew S Squires, Marco Ladetto, MD, Nikhil C. Munshi, MD, Mario Boccadoro, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2008) 112 (11): 251.

https://doi.org/10.1182/blood.V112.11.251.251

Published: 2008

Journal Articles

CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM)

Hiroshi Ikeda, MD, PhD, Teru Hideshima, MD, PhD, Yutaka Okawa, MD, PhD, Sonia Vallet, MD, Samantha Pozzi, Loredana Santo, MD, Gullu Gorgun, Mariateresa Fulciniti, Noopur S. Raje, MD, Giulia Perrone, Nikhil Munshi, MD, Paul Richardson, MD, Brian J Lannutti, Kamal D. Puri, Neill A. Giese, Kenneth C. Anderson, MD

Blood (2008) 112 (11): 2753.

https://doi.org/10.1182/blood.V112.11.2753.2753

Published: 2008

Journal Articles

Halofuginone, a Novel Antimyeloma Agent, Upregulates C-Jun, JNK and P-53 Protein in Vitro , and Inhibits Tumor Growth and Improves Survival in in Vivo M ultiple Myeloma(MM) Animal Models

Merav Leiba, MD, Jana Jakubikova, Steffen Klippel, Constantine S. Mitsiades, MD, PhD, Teru Hideshima, Yu-Tzu Tai, Paul Richardson, Yutaka Okawa, Hiroshi Ikeda, Arnon Nagler, Kenneth C. Anderson

Blood (2008) 112 (11): 2754.

https://doi.org/10.1182/blood.V112.11.2754.2754

Published: 2008

Journal Articles

RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDKDependent and Independent Survival Mechanisms

Diana Cirstea, M.D., Teru Hideshima, M.D., Ph.D., Samantha Pozzi, M.D., Sonia Vallet, M.D., Hiroshi Ikeda, M.D., Ph.D., Loredana Santo, M.D., Hannes Loferer, Nileshwari Vaghela, M.B.S., Yutaka Okawa, M.D., Ph.D., Giulia Perrone, M.D., Gullu Gorgun, Ph.D., Elisabetta Calabrese, M.D., Nikhil C. Munshi, MD, Kenneth C. Anderson, M.D., Noopur Raje, M.D.

Blood (2008) 112 (11): 2759.

https://doi.org/10.1182/blood.V112.11.2759.2759

Published: 2008

Journal Articles

Combination of Nab -Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM)

Blood (2008) 112 (11): 3663.

https://doi.org/10.1182/blood.V112.11.3663.3663

Published: 2008

Journal Articles

Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition

Giulia Perrone, Teru Hideshima, MD, PhD, Hiroshi Ikeda, Yutaka Okawa, Diana Cristea, Loredana Santo, Gullu Gorgun, Elisabetta Calabrese, Noopur Raje, Michele Baccarani, Michele Cavo, Kenneth C. Anderson, MD

Blood (2008) 112 (11): 3687.

https://doi.org/10.1182/blood.V112.11.3687.3687

Published: 2008

Journal Articles

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.

Blood (2008) 112 (11): 1716.

https://doi.org/10.1182/blood.V112.11.1716.1716

Published: 2008

Journal Articles

In Vivo Effects of Zoledronic Acid on Bone Remodeling.

Samantha Pozzi, MD, Teru Hideshima, MD, Sonia Vallet, MD, Siddhartha Mukherjee, MD, Shweta Chhetri, Diana Cirstea, MD, Nileshwari Vaghela, Clare Thomas, Dilani Rosa, Hiroshi Ikeda, MD, Yutaka Okawa, MD, Tanyel Kiziltepe, PhD, Jesse Schoonmaker, Ernestina Schipani, MD, Mary Bouxsein, PhD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2007) 110 (11): 3520.

https://doi.org/10.1182/blood.V110.11.3520.3520

Published: 2007

Journal Articles

Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.

Sonia Vallet, MD, Noopur Raje, MD, MariaTeresa Fulciniti, Kenji Ishitsuka, MD, Teru Hideshima, MD, Klaus Podar, MD, Samantha Pozzi, MD, Iris Breitkreutz, MD, Tanyel Kiziltepe, PhD, Yutaka Okawa, MD, Hiroshi Ikeda, MD, Loredana Santo, MD, Siddhartha Mukherjee, MD, Nileshwari Vaghela, Diana Cirstea, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 2503.

https://doi.org/10.1182/blood.V110.11.2503.2503

Published: 2007

Journal Articles

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Blood (2007) 110 (11): 256.

https://doi.org/10.1182/blood.V110.11.256.256

Published: 2007

Journal Articles

Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment.

Yutaka Okawa, Teru Hideshima, Hiroshi Ikeda, Sonia Vallet, Tanyel Kiziltepe, Noopur Raje, Hiroshi Yasui, Sotaro Enatsu, Samantha Pozzi, Iris Breitkreutz, Klaus Podar, Paul G. Richardson, Kenneth C. Anderson

Blood (2007) 110 (11): 2522.

https://doi.org/10.1182/blood.V110.11.2522.2522

Published: 2007

Journal Articles

Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.

Sonia Vallet, MD, Teru Hideshima, MD, Samantha Pozzi, MD, Nileshwari Vaghela, Gaurav Gharti-Chhetri, Siddhartha Mukherjee, MD, Iris Breitkreutz, MD, Tanyel Kiziltepe, PhD, Yutaka Okawa, MD, Hiroshi Ikeda, MD, Loredana Santo, MD, Diana Cirstea, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2007) 110 (11): 4764.

https://doi.org/10.1182/blood.V110.11.4764.4764

Published: 2007

Journal Articles

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

Teru Hideshima, MD, PhD, Noopur Raje, MD, Ruben Carrasco, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Tanyel Kiziltepe, PhD, Sonia Valet, MD, Samantha Pozzi, MD, Dharminder Chauhan, PhD, Constantine Mitsiades, MD, PhD, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 670.

https://doi.org/10.1182/blood.V110.11.670.670

Published: 2007

Journal Articles

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

Blood (2007) 110 (10): 3744–3752.

https://doi.org/10.1182/blood-2007-05-093294

Published: 2007

Includes: Supplemental data

Journal Articles

Epigenetic Modulation by Vidaza™ induces Apoptosis and Overcomes In Vitro Drug Resistance in Human Multiple Myeloma Cells.

Tanyel Kiziltepe, PhD, Laurence Catley, MD, Teru Hideshima, MD,PhD, Noopur Raje, MD, Hiroshi Yasui, MD,PhD, Sonia Vallet, MD, Hiroshi Ikeda, MD,PhD, Yutaka Okawa, MD,PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 5001.

https://doi.org/10.1182/blood.V108.11.5001.5001

Published: 2006

Journal Articles

Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway.

Hiroshi Yasui, MD, PhD, Teru Hideshima, M.D., Ph.D., Hiroshi Ikeda, M.D., Ph.D., Enrique M. Ocio, M.D., Ph.D., Tanyel Kiziltepe, Ph.D., Sonia Vallet, M.D., Ph.D., Yutaka Okawa, M.D., Ph.D., Shweta Chhetri, Kumar Sukhdeo, Kenji Ishitsuka, M.D., Ph.D., Klaus Podar, M.D., Ph.D., Noopur Raje, M.D., Ph.D., Dharminder Chauhan, Ph.D., Daniel R. Cattasco, M.D., Ph.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 5005.

https://doi.org/10.1182/blood.V108.11.5005.5005

Published: 2006

NARROW

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β

CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM)

Halofuginone, a Novel Antimyeloma Agent, Upregulates C-Jun, JNK and P-53 Protein in Vitro , and Inhibits Tumor Growth and Improves Survival in in Vivo M ultiple Myeloma(MM) Animal Models

RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDKDependent and Independent Survival Mechanisms

Combination of Nab -Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM)

Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.

In Vivo Effects of Zoledronic Acid on Bone Remodeling.

Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment.

Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

Epigenetic Modulation by Vidaza™ induces Apoptosis and Overcomes In Vitro Drug Resistance in Human Multiple Myeloma Cells.

Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only